Publisher
Springer Science and Business Media LLC
Subject
Pharmacology (medical),Pharmacology
Reference15 articles.
1. Yu Y, Maliepaard M. Comment on: “Levothyrox® new and old formulations: are they switchable for millions of patients?”. Clin Pharmacokinet. 2019. https://doi.org/10.1007/s40262-019-00850-5.
2. U.S. Department of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research (CDER). Guidance for industry: statistical approaches to establishing bioequivalence. January 2001. https://www.fda.gov/media/70958/download. [Accessed 26 Nov 2019].
3. Concordet D, Gandia P, Montastruc J-L, Bousquet-Mélou A, Lees P, Ferran AA, et al. Authors’ reply to Coste et al.: Levothyrox® new and old formulations: are they switchable for millions of patients? Clin Pharmacokinet. 2019;58(7):967–8. https://doi.org/10.1007/s40262-019-00747-3.
4. Concordet D, Gandia P, Montastruc J-L, Bousquet-Mélou A, Lees P, Ferran AA, et al. Why were more than 200 subjects required to demonstrate the bioequivalence of a new formulation of levothyroxine with an old one? Clin Pharmacokinet. 2019. https://doi.org/10.1007/s40262-019-00812-x.
5. Anonymous. Draft guidance on levothyroxine sodium. Food and Drug Administration; 2018: :p. 2. https://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM428208.pdf. Accessed 4 Oct 2019.
Cited by
1 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献